Abstract
In the last years, tumor genomic testing has drastically changed the prognosis of patients especially in those treated for an advanced/metastatic nonsquamous non–small-cell lung cancer (NSCLC). Lung cancer is associated with older age. However considering the heterogeneity of this population it remains unclear whether older patients are screened in the same proportion as younger patients. This study aims to compare the proportion of molecular testing performed in advanced or metastatic nonsquamous NSCLC at diagnosis between patients aged ≥ 70 years old, and their younger counterparts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
